Piperine: A Comprehensive Reference Article
1. Identity: Chemical and Botanical Characterization
1.1 Nomenclature and Chemical Identity
Piperine is a naturally occurring alkaloid amide that serves as the primary bioactive compound responsible for the pungent, biting taste of black pepper (Piper nigrum) and long pepper (Piper longum). With the chemical formula C₁₇H₁₉NO₃ and a molecular weight of 285.34 g/mol, it appears as a light yellow to yellow crystalline solid with a pungent odor, exhibiting low solubility in water but good solubility in ethanol and ether. Piperine is weakly basic and can be hydrolyzed into piperic acid and piperidine.
Chemically speaking, piperine consists of a piperidine nucleus linked to an aromatic part containing methylenedioxyphenyl. Specifically, it is an amide, containing an amide linkage connecting a piperidine ring to a long side chain. The compound is formally known as 1-piperoylpiperidine, and belongs to the alkaloid class of nitrogen-containing natural products. Piperine is insoluble in cold water and poorly soluble in hot water.
1.2 Discovery
The compound itself was first isolated in 1819 by Danish chemist and physicist Hans Christian Ørsted, who extracted a yellow crystalline substance from the fruits of Piper nigrum using ethanol as the solvent. Ørsted, renowned for his foundational work in electromagnetism, identified this alkaloid as the key pungent component and named it piperine, derived from the botanical genus Piper. This isolation marked one of the earliest extractions of a plant alkaloid, highlighting piperine's role in the sensory qualities long attributed to pepper.
1.3 Natural Sources and Content
Piperine is a compound belonging to the alkaloids and has, in addition to being found in members of the Piperaceae family, been detected in several other plant species (Rhododendron faurie, Vicoa indica, Anethum sowa, and others). The amount of piperine is highest in Piper nigrum L., and varies from 2% to as high as 9%, depending on environmental factors such as climate and/or place of origin, as well as growing conditions.
Piperine constitutes 2% to 7.4% of both black pepper and white pepper (Piper nigrum L.), although some reports pointed to higher piperine content of black pepper up to 9%, 4% of long pepper (Piper longum L.) fruits, and 4.5% of Balinese long pepper fruits (Piper retrofractum Vahl).
Piperine is found in black, green and white pepper (Piper nigrum), and in other plants such as long pepper (Piper longum), cubeb or tailed pepper (Piper cubeba), and in Java pepper (Piper retrofractum). In addition to plants of the Piper genus, piperine is also found in many other plant species, including celery seeds (Anethum graveolens) and in African pepper or Guinea pepper (Xylopia aethiopica).
1.4 Common Forms and Preparations
BioPerine®, a well-known commercial standardized extract, is prepared from dried fruits of Piper nigrum and contains a minimum of 95% piperine. It is clinically studied for its ability to enhance the bioavailability of nutrients. It has been recognized as a bioavailability enhancer for nearly two decades, and is one of the few sources of black pepper to have undergone clinical studies in the United States and several other countries.
Piperine is available in multiple supplement dosage forms. These include tablets, gummies, liquid, powder, pills, and capsules. It is also frequently incorporated as a minor ingredient in multi-ingredient supplement formulations alongside compounds such as curcumin, resveratrol, and various vitamins and minerals. In the food context, piperine is present in whole and ground black pepper used in cooking.
2. Traditional and Historical Use
2.1 Ayurvedic Medicine
Black pepper (Piper nigrum L.) is the most used among the pepper species, and along with its worldwide utilization as a spice, it is known as an important medicinal plant. Its traditional use can be traced to thousands of years ago, due to its unique role in Ayurvedic medicine, where it represents one of the components of "trikatu" (equal proportions of black pepper, long pepper, and ginger). Trikatu or its individual compounds are the base for 210 out of 370 formulations listed in traditional texts. Pepper is traditionally recommended for fevers and a variety of gastrointestinal conditions, as well as for neurological and broncho-pulmonary disorders (asthma and chronic bronchitis).
Black pepper constitutes one third of the famous Ayurvedic formula trikatu (along with ginger and long pepper). This formula is used to stimulate circulation, digestion, and for lung problems accompanied by sticky mucus. In Ayurveda, black pepper has been revered not just for its flavor, but for its potent healing properties. Its key use is to stimulate the digestive fire (agni), enhancing appetite and nutrient absorption while reducing bloating and gas.
The earliest recorded mention of long pepper (a major piperine source) appears in the Charaka Samhita (circa 100 BCE), where it is celebrated for balancing Vata and Kapha. Later, the Sushruta Samhita (circa 500 CE) describes its use in respiratory therapies — often combined with honey and ghee to soothe chronic coughs.
Black pepper also has a long history of external use in Ayurveda on inflamed skin when mixed with oil or used as a poultice. In traditional Ayurvedic and Chinese medicine, black pepper and piperine-rich preparations have been used as remedies for a wide range of ailments, including indigestion, respiratory disorders, and inflammation.
2.2 Traditional Chinese Medicine
Traditional Chinese medicine utilizes black pepper for the treatment of various pains (headaches, muscular pain), rheumatism, infections such as strep throat and influenza, as well as for enhancing the blood circulation.
2.3 Other Traditional Systems
In Persia, Unani physicians like Avicenna mentioned long pepper under the name "Filfil hindi," using it in digestive and respiratory syrups, sometimes blended with rose water and honey. Medieval Arabic manuscripts detailed recipes for "piperine cordial" to treat digestive weakness. In Himalayan Tibetan medicine, pippali was integrated into the famous "Three Kings" formula, combining it with ginger and black pepper to alleviate high-altitude coughs.
During the medieval period, pepper not only enhanced cuisine but also held medicinal significance in European apothecaries for treating ailments like indigestion and fever, driving economic motivations that later spurred European exploration and colonization efforts.
Piperine's ability to enhance the absorption and bioavailability of other herbal compounds has made it an invaluable component in herbal combinations throughout history. For example, in Ayurveda, black pepper is a crucial ingredient in the renowned formulation Trikatu, which also contains ginger and long pepper.
3. Key Constituents and Active Compounds
3.1 Piperine as the Primary Active Compound
In addition to piperine, pepper contains fibers, starch, proteins, carbohydrates, lignans, alkaloids, flavonoids, phenols, amides, and essential oil. However, piperine is recognized as the dominant pharmacologically active constituent. The alkaloid piperine is the key phytoconstituent of the plant, primarily responsible for its pharmacological impacts.
3.2 Piperine Isomers and Related Compounds
Piperine has several geometric isomers — including chavicine, isochavicine, and isopiperine — which also occur in black pepper, though at far lower concentrations and with less pharmacological activity than piperine itself. The molecular basis for the pleiotropic activities of piperine is based on its ability to regulate multiple signaling molecules such as cell cycle proteins, anti-apoptotic proteins, P-glycoprotein, cytochrome P450 3A4, multidrug resistance protein 1, breast cancer resistance protein, transient receptor potential vanilloid 1 (TRPV1), proinflammatory cytokines, nuclear factor-κB (NF-κB), COX-2, nitric oxide synthases-2, and others.
4. Established Mechanisms of Action
4.1 Inhibition of Drug-Metabolizing Enzymes (Bioenhancement)
Piperine (1-piperoylpiperidine), a major component extracted from black pepper, was reported to be an inhibitor of the activity of human CYP3A4 and MDR1 (P-glycoprotein), resulting in increased bioavailability of orally co-administered drugs that were CYP3A4 and MDR1 substrates.
Both CYP3A4, the major phase I drug metabolizing enzyme in humans, and the multidrug efflux pump P-glycoprotein (P-gp), are present at high levels in the villus enterocytes of the small intestine, the primary site of absorption for orally administered drugs. Moreover, these proteins are induced by many of the same compounds and demonstrate a broad overlap in substrate and inhibitor specificities, suggesting that they act as a concerted barrier to drug absorption.
Piperine has been found to inhibit CYP-mediated pathways along with phase II metabolism. As a result, piperine increases the bioavailability of a variety of drugs, including phenytoin, midazolam, propranolol, and theophylline. Using meta-analysis, researchers concluded that piperine has potency to inhibit CYP2C9, CYP2E1, and CYP3A4 substrates.
An important complexity was identified regarding piperine's dual effects on these enzymes. In vitro and in vivo measurements showed that piperine could activate the transcriptional activity of human PXR (pregnane X receptor) and subsequently induce the expression of CYP3A4 and MDR1 in human intestine cells and hepatocytes — revealing a dichotomous effect of piperine that may complicate predictions of its net effect on drug metabolism in chronic use.
4.2 Anti-inflammatory Mechanisms
In cell studies, piperine at concentrations of 10–20 mg/L attenuated the production of nitric oxide (NO) and reactive oxygen species (ROS), downregulated the protein and mRNA expression levels of TNF-α, IL-1β, and IL-6, and upregulated the protein and mRNA transcription levels of IL-10. Additionally, piperine inhibited the phosphorylation levels of the ERK, JNK, p38, and p65 proteins. This indicates activity through both the MAPK and NF-κB signaling pathways.
Piperine has been shown to have anti-inflammatory activity through the suppression of cyclooxygenase (COX)-2 gene expression and enzyme activity, and is also reported to exhibit anti-platelet activity. Piperine significantly suppressed arachidonic acid liberation by attenuating cytosolic phospholipase A₂ (cPLA₂) activity in collagen-stimulated platelets, and significantly inhibited the activity of thromboxane A₂ (TXA₂) synthase, but not of COX-1, in platelets.
4.3 Antioxidant Mechanisms
Piperine, having an anti-inflammatory effect, has been demonstrated in in vitro experiments to protect against oxidative damage by inhibiting or quenching free radicals and reactive oxygen species and hydroxyl radicals. Piperine was found to act as a hydroxyl radical scavenger at low concentrations, but at higher concentrations, it activated the Fenton reaction resulting in increased generation of hydroxyl radicals. At superoxide scavenging, an IC₅₀ of 1.82 mM was observed, and a 52% inhibition of lipid peroxidation was observed at a dose of 1400 μM. This concentration-dependent duality is an important nuance: antioxidant effects are seen at lower concentrations, and the reverse may occur at higher doses.
4.4 TRPV1 Receptor Activation
Piperine activates TRPV1 (transient receptor potential vanilloid type-1) receptors in the body, which can temporarily desensitize pain receptors and provide relief. This mechanism underlies both its pungency and its proposed analgesic properties.
4.5 Neuroprotective Mechanisms
It has been demonstrated that piperine can penetrate the blood–brain barrier, protect against ischemic brain injury and kainate-induced seizures or neurotoxicity, attenuate β-amyloid or oxidative stress-induced neuronal cell damage and death, and improve depression-like behavior and cognitive impairment. These findings are, however, based primarily on animal and cell models. Despite the compelling evidence for the neuroprotective effects of piperine, its mechanism of action is not fully clarified.
5. Scientific Evidence by Area of Use
5.1 Bioavailability Enhancement — The Best-Documented Activity
The most extensively studied and clinically documented application of piperine is as a "bioenhancer" — a compound that increases the absorption or bioavailability of co-administered substances.
Curcumin: The landmark human study in this field was conducted by Shoba et al. (1998) and published in Planta Medica. The co-administration of 2 g/kg curcumin and 20 mg/kg piperine to rats produced higher serum curcumin concentrations at 1 and 2 hours after oral administration. The pharmacokinetic parameters of curcumin changed by piperine included increased Tmax, decreased elimination half-life, and total clearance elimination — overall, curcumin bioavailability in rats was increased by 154%. In humans, the pharmacokinetic changes were more evident, since the bioavailability of curcumin was 2,000% increased 45 minutes after co-administration with piperine.
The specific details of the human arm of that study: Piperine was administered at 20 mg in humans with curcumin at 2 g total (a single dose). The study showed that in the dosages used, piperine enhances the serum concentration, extent of absorption, and bioavailability of curcumin in both rats and humans with no adverse effects.
However, the Shoba et al. finding requires careful interpretation. The "curcumin only" control group returned results below the limit of detection for curcumin in serum, and the value of a 2,000% increase was based on the AUC measurement. It is not clear from this study what assumptions were made regarding the non-detects in serum when estimating AUC. The 2,000% bioavailability claim has never been independently replicated. Additionally, the study was industry-sponsored and was not randomized or double-blind. In another study, human subjects receiving for one week 2 g curcumin with 5 mg piperine also showed increased plasma curcumin levels (2-fold) in comparison with individuals receiving only curcumin, 2 hours after the last administration.
Other nutrients: BioPerine® has been shown to significantly enhance the bioavailability of several supplement nutrients, such as β-carotene, L(+)-Selenomethionine, Se-methyl-L-selenocysteine, vitamin B6, vitamin C, coenzyme Q10 (CoQ10), curcumin, resveratrol, ginseng, and elemental iron through their increased absorption.
Pharmaceutical drugs: In a study in 12 healthy subjects, a single dose of carbamazepine 200 mg was given before and after administration of piperine 20 mg/day for 10 days. Carbamazepine area under the curve (AUC) increased by 48% after administration of piperine. The study was not double-blind and did not use a randomized, crossover method, but the results are consistent with previous studies suggesting that piperine inhibits CYP3A4.
In another study, 12 healthy subjects took a single 120-mg dose of fexofenadine before and after administration of piperine 20 mg/day for 10 days. With piperine pretreatment, fexofenadine AUC increased by 68%, but fexofenadine half-life was not significantly affected. The authors proposed that piperine inhibits P-glycoprotein (PGP), thus increasing fexofenadine bioavailability. Previous evidence from in vitro and animal studies does suggest that piperine inhibits PGP, but more clinical evidence is needed to determine if piperine interacts with other PGP substrates with a greater risk of toxicity, such as digoxin.
Evidence strength: The bioavailability-enhancing effect is the most robustly documented activity of piperine in humans. Multiple clinical studies, a systematic review and meta-analysis, and pharmacokinetic studies in healthy volunteers confirm this effect across a range of drug substrates. The magnitude of the effect varies considerably by co-substrate, and study methodology in this area is frequently non-blinded and unrandomized.
5.2 Anti-inflammatory and Antioxidant Effects
In vitro and in vivo data provide deep insight into the mechanisms of piperine action, which are related to its antioxidant and anti-inflammatory efficacy, together with its ability to interfere with several molecular signaling pathways. Studies have shown piperine to have high antioxidant activity, which aids in reducing oxidative stress and preventing cellular damage. Its anti-inflammatory effects have been established as suppressing the generation of pro-inflammatory mediators, thereby relieving inflammation-related diseases.
Evidence strength: The anti-inflammatory and antioxidant evidence for piperine is predominantly preclinical (cell culture and animal models). Robust, large randomized controlled trials in humans specifically targeting isolated piperine for inflammatory endpoints are limited. Some clinical studies examining curcumin+piperine combinations have reported anti-inflammatory outcomes, but the contribution of piperine alone cannot be isolated from these trials.
5.3 Neuroprotection and Cognitive Function
Preliminary research has examined piperine's potential effects on the central nervous system. Animal studies suggest that piperine may inhibit certain enzymes involved in the breakdown of neurotransmitters, and may help reduce oxidative stress in brain tissue. Some researchers have investigated its potential relevance to conditions involving cognitive decline, with early findings suggesting a possible neuroprotective role. These results are, however, based primarily on animal models and should not be interpreted as established clinical evidence for any brain health benefit in humans.
Piperine is investigated for potential therapeutic benefits in patients suffering from Parkinson's disease, Alzheimer's disease, and cerebral stroke, but these are largely at the preclinical or early-clinical investigational stage.
Evidence strength: Preliminary; predominantly animal and in vitro data. Human clinical evidence for neurological benefit from piperine alone is insufficient to draw conclusions.
5.4 Anticancer Properties
Cell study results indicated that piperine modified morphology and inhibited viability and formation of cell colonies in head and neck cancer cell lines. Piperine promoted genotoxicity by triggering apoptosis and cell cycle arrest in the G2/M and S phases. A decrease in cell migration was observed, and there was decreased expression of MMP2/9 genes. Piperine also reduced the expression of inflammatory molecules (PTGS2 and PTEGER4) and regulated the secretion of cytokines.
The antitumor potential of piperine, demonstrated through its apoptotic effect on many cancer types, should be further investigated, especially in the form of human clinical trials, since such data do not exist.
Evidence strength: Preclinical only (in vitro cell lines and some animal models). No human clinical trials have investigated piperine as an anticancer agent.
5.5 Metabolic and Weight Management Effects
Piperine exhibits pleiotropic properties including antihypertensive and hepatoprotective activities, and has been investigated in the context of metabolic syndrome and obesity. Piperine has been associated with potential therapeutic benefits in patients suffering from diabetes, obesity, metabolic syndrome, and cardiovascular diseases, though it must be emphasized that most of this evidence comes from preclinical research or early-phase clinical investigations of limited size.
Evidence strength: Largely preclinical. Some early clinical studies exist regarding metabolic markers, but high-quality evidence is lacking. Piperine has attracted interest in the context of weight management through several proposed mechanisms, but robust human RCT evidence for meaningful weight or metabolic outcomes is not yet available.
5.6 Digestive and Gastrointestinal Effects
In traditional Ayurvedic and Chinese medicine, black pepper and piperine-rich preparations have been used as remedies for indigestion and similar ailments. Historical records indicate that black pepper infusions were commonly administered to support digestive health, promote detoxification, and stimulate appetite. Mechanistically, piperine is thought to stimulate digestive enzyme activity. Piperine has the ability to alter gastrointestinal disorders and drug-metabolizing enzymes.
Evidence strength: Historically well-documented traditional use; modern mechanistic plausibility, but large human clinical trial evidence for specific gastrointestinal conditions is limited.
6. Body Systems Associated with Piperine
- Gastrointestinal system: Stimulation of digestive enzymes, motility, and nutrient absorption; historical use for indigestion, gas, and appetite.
- Hepatic and metabolic system: Modulation of CYP450 enzymes (CYP3A4, CYP2C9, CYP2E1) and phase II conjugation pathways affecting drug and nutrient metabolism.
- Immune/inflammatory system: Downregulation of NF-κB, MAPK signaling, COX-2, and pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) in preclinical models.
- Central nervous system: Potential penetration of the blood–brain barrier; neuroprotective and possible antidepressant effects demonstrated in animals.
- Cardiovascular system: Anti-platelet effects (inhibition of TXA₂ synthase and cPLA₂) observed in preclinical studies.
- Respiratory system: Traditional use for bronchitis, asthma, and respiratory congestion, particularly in Ayurvedic trikatu.
Piperine possesses remarkable biological properties, including antioxidant, anti-inflammatory, antibacterial, anticancer, neuroprotective, and hepatoprotective qualities. Its ability to affect numerous signaling pathways and biological targets implicated in disease development is responsible for these functions.
7. Dosage Forms and Dosages Reported in Studies
Piperine is used at varying doses depending on the intended application. The following dosages are as reported in the cited sources:
- In the landmark Shoba et al. (1998) human bioavailability study, piperine was administered at 20 mg with curcumin at 2 g total as a single dose.
- Increased bioavailability of certain drugs has been observed in several human studies with bolus doses of 20 mg/day (identified as the LOEL — lowest observed effect level), and findings with β-carotene and coenzyme Q10 suggest that in some cases bolus doses of 5 mg piperine/day might also cause such interactions.
- Human studies with repeated piperine administrations comprise only a small number of studies using piperine without concomitant administration of other substances, including drug interaction studies with piperine-only run-in phases of 3–10 days and piperine doses of 15–20 mg/day.
- In the carbamazepine interaction study, piperine was administered at 20 mg/day for 10 days.
- In human single-dose studies, piperine doses of 50 or 500 mg were applied either alone (50 mg piperine) or in combination (500 mg piperine) with curcumin.
- In a randomized controlled trial of exercise recovery, participants consumed 2 g of curcumin and 20 mg of piperine, 3 times a day.
- For bioavailability enhancement, the typical dosage range of piperine used in studies is 5–20 mg per day, particularly when co-administered with curcumin.
- In one crossover pharmacokinetics study, 15 mg of a pepper extract standardized to 95% piperine (BioPerine®) was combined with 1500 mg of a turmeric extract standardized to 95% curcuminoids.
BioPerine®, a standardized extract prepared from dried fruits of Piper nigrum, contains a minimum of 95% piperine and is formulated in capsule and tablet form at various strengths. The compound can also be obtained directly from dietary black pepper, though concentrations in food are lower and variable.
8. Safety Considerations and Drug Interactions
8.1 General Safety
Although the available human studies rarely reported effects that were regarded as being adverse, their suitability for detailed risk assessment is limited due to an insufficient focus on safety parameters apart from drug interactions, as well as due to the lack of investigation of potentially adverse effects observed in animal studies and/or combined administration of piperine with other substances.
Taken together, it appears advisable to consider the potential health risks related to intake of isolated piperine in bolus form, e.g., when using certain food supplements.
8.2 Drug Interactions — A Clinically Significant Concern
In human and animal studies with single or short-term bolus application of isolated piperine, interactions with several drugs — in most cases resulting in increased drug bioavailability — were observed. Depending on the drug and extent of the interaction, such interactions may carry the risk of unintended, deleteriously increased, or adverse drug effects.
By enhancing bioavailability, piperine can reduce the required dosage, lower drug costs, minimize the occurrence of drug resistance, and mitigate dose-dependent side effects associated with various medications such as ciprofloxacin, ampicillin, metronidazole, carbamazepine, curcumin, and oxytetracycline. However, this same mechanism also carries risk. A limited number of published studies have indicated a reduction in bioavailability following oral administration of isoniazid, puerarin, diltiazem, desacetyldiltiazem, and magnolol in combination with piperine or pepper/Trikatu.
Results of recent reports suggest that piperine may increase plasma concentrations of carbamazepine and diclofenac through inhibition of CYP3A4 and CYP2C9, respectively.
The dichotomous effects of piperine on induction of CYP3A4 and MDR1 expression observed in some research, and inhibition of their activity reported elsewhere, challenges the potential use of piperine as a bioavailability enhancer and suggests that cautions should be taken for piperine consumption during drug treatment in patients, particularly those who favor daily pepper spice or rely on certain pepper remedies.
8.3 Reproductive Toxicity (Animal Data)
Animal studies with higher daily piperine bolus doses than in human interaction studies provide indications of disturbance of spermatogenesis and of maternal reproductive and embryotoxic effects. The only toxic effect frequently indicated in studies is adverse reproductive effects in males (impaired spermatogenesis) when piperine is used in bolus doses of 10 mg/kg body weight/day. However, in one study of 60 days in mice administered piperine, it was shown that after a withdrawal period of 120 days, the changes were reversible.
It is important to note that these reproductive findings come from animal research; the doses used in animal studies (mg/kg body weight) are substantially higher than the 5–20 mg/day doses typically used in human supplement studies. Whether these effects translate to humans at typical supplemental doses has not been established.
8.4 Interaction with Glucuronidation
Formulations containing piperine act by inhibiting the glucuronidation, which may cause serious health risks, as glucuronidation is protective against many toxins and is involved in the metabolism of commonly used drugs. Inhibition of glucuronidation — a key phase II detoxification pathway — represents a mechanism through which piperine may alter the balance of drug metabolism in ways that are not always predictable.
8.5 Summary of Interaction Evidence
A comprehensive pharmacokinetic drug interaction evaluation of piperine encompassed a total of 34 scholarly articles (specific for pharmacokinetic interactions), consisting of 62 studies — 56 preclinical studies and 6 clinical investigations. The co-administration of piperine has been observed to induce subtle modifications in the absorption, membrane transport, and drug metabolism of several high-efficacy medicines. The occurrence of medication interactions might have a notable impact on the pharmacokinetic parameters, resulting in either a favorable or unfavorable pharmacological effect.
References
Volver